Sartorius Stedim Biotech (DIM) Stock Forecast & Price Target

Compare

15 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DIM Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Sartorius

Stedim Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DIM Stock 12 Month Forecast

Average Price Target

€229.38

▲(36.86% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €229.38 with a high forecast of €245.00 and a low forecast of €210.00. The average price target represents a 36.86% change from the last price of €167.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"145":"€145","246":"€246","170.25":"€170.3","195.5":"€195.5","220.75":"€220.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€245.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":229.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€229.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€210.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[145,170.25,195.5,220.75,246],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.65,177.2923076923077,182.9346153846154,188.5769230769231,194.21923076923076,199.86153846153846,205.50384615384615,211.14615384615385,216.78846153846155,222.43076923076922,228.07307692307694,233.7153846153846,239.3576923076923,{"y":245,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.65,176.09076923076924,180.53153846153847,184.9723076923077,189.41307692307691,193.85384615384615,198.29461538461538,202.73538461538462,207.17615384615385,211.61692307692306,216.05769230769232,220.49846153846153,224.93923076923076,{"y":229.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.65,174.6,177.55,180.5,183.45000000000002,186.4,189.35,192.3,195.25,198.2,201.15,204.1,207.05,{"y":210,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":181.959,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.145,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.454,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.093,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.753,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.116,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.987,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.556,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.959,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€245.00

Average Price Target€229.38

Lowest Price Target€210.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

€174

Hold

3.82%

Upside

Reiterated

08/06/25

Sartorius Stedim Biotech's overall stock score is primarily influenced by its solid financial performance, despite challenges in growth and cash flow management. The technical analysis indicates bearish momentum, which is a significant risk factor. The high P/E ratio suggests overvaluation, further impacting the stock's attractiveness. The absence of earnings call and corporate events data limits additional insights.

Charles Pitman CFABarclays

Barclays

€250→€240

Buy

43.20%

Upside

Reiterated

07/23/25

Barclays Reaffirms Their Buy Rating on Sartorius Stedim Biotech (0RG8)

Richard VosserJ.P. Morgan

J.P. Morgan

€230→€225

Buy

34.25%

Upside

Reiterated

07/23/25

Sartorius Stedim Biotech (0RG8) Gets a Buy from J.P. Morgan

Charles WestonRBC Capital

RBC Capital

€240→€230

Buy

37.23%

Upside

Upgraded

07/23/25

Positive Report for Sartorius Stedim Biotech (0RG8) from RBC Capital

James QuigleyGoldman Sachs

Goldman Sachs

€234→€232

Buy

38.42%

Upside

Reiterated

07/23/25

Sartorius Stedim Biotech (0RG8) Receives a Buy from Goldman Sachs

Oliver ReinbergKepler Capital

Kepler Capital

€210

Hold

25.30%

Upside

Reiterated

07/22/25

Sartorius Stedim Biotech (0RG8) Receives a Hold from Kepler Capital

Matthew WestonUBS

UBS

€220

Hold

31.26%

Upside

Reiterated

07/08/25

UBS Sticks to Its Hold Rating for Sartorius Stedim Biotech (0RG8)

Odysseas ManesiotisExane BNP Paribas

Exane BNP Paribas

€233

Buy

39.02%

Upside

Initiated

05/29/25

Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas

James VaneJefferies

Jefferies

€245

Buy

46.18%

Upside

Reiterated

05/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Thibault BoutherinMorgan Stanley

Morgan Stanley

€260→€250

Buy

49.16%

Upside

Reiterated

04/22/25

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR250 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR250.00 (from EUR260.00) while maintaining a Overweight rating.

Delphine Le LouetBernstein

Bernstein

€234

Hold

39.62%

Upside

Reiterated

04/16/25

Sartorius Stedim Biotech (0RG8) Gets a Hold from Bernstein

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

€174

Hold

3.82%

Upside

Reiterated

08/06/25

Charles Pitman CFABarclays

Barclays

€250→€240

Buy

43.20%

Upside

Reiterated

07/23/25

Barclays Reaffirms Their Buy Rating on Sartorius Stedim Biotech (0RG8)

Richard VosserJ.P. Morgan

J.P. Morgan

€230→€225

Buy

34.25%

Upside

Reiterated

07/23/25

Sartorius Stedim Biotech (0RG8) Gets a Buy from J.P. Morgan

Charles WestonRBC Capital

RBC Capital

€240→€230

Buy

37.23%

Upside

Upgraded

07/23/25

Positive Report for Sartorius Stedim Biotech (0RG8) from RBC Capital

James QuigleyGoldman Sachs

Goldman Sachs

€234→€232

Buy

38.42%

Upside

Reiterated

07/23/25

Sartorius Stedim Biotech (0RG8) Receives a Buy from Goldman Sachs

Oliver ReinbergKepler Capital

Kepler Capital

€210

Hold

25.30%

Upside

Reiterated

07/22/25

Sartorius Stedim Biotech (0RG8) Receives a Hold from Kepler Capital

Matthew WestonUBS

UBS

€220

Hold

31.26%

Upside

Reiterated

07/08/25

UBS Sticks to Its Hold Rating for Sartorius Stedim Biotech (0RG8)

Odysseas ManesiotisExane BNP Paribas

Exane BNP Paribas

€233

Buy

39.02%

Upside

Initiated

05/29/25

Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas

James VaneJefferies

Jefferies

€245

Buy

46.18%

Upside

Reiterated

05/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Thibault BoutherinMorgan Stanley

Morgan Stanley

€260→€250

Buy

49.16%

Upside

Reiterated

04/22/25

Delphine Le LouetBernstein

Bernstein

€234

Hold

39.62%

Upside

Reiterated

04/16/25

Sartorius Stedim Biotech (0RG8) Gets a Hold from Bernstein

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sartorius Stedim Biotech

1 Month

xxx

Success Rate

5/8 ratings generated profit

Average Return

+1.25%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +1.25% per trade.

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+1.18%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +1.18% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

4/18 ratings generated profit

Average Return

-10.85%

reiterated a buy rating 17 days ago

Copying Richard Vosser's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -10.85% per trade.

2 Years

xxx

Success Rate

0/18 ratings generated profit

Average Return

-20.48%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -20.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DIM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DIM has received 5 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. DIM average Analyst price target in the past 3 months is 229.38.

Each month's total comprises the sum of three months' worth of ratings.

DIM Financial Forecast

DIM Earnings Forecast

Next quarter’s earnings estimate for DIM is €0.98 with a range of €0.81 to €1.09. The previous quarter’s EPS was €1.22. DIM beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year DIM has Outperformed its overall industry.

DIM Sales Forecast

Next quarter’s sales forecast for DIM is €709.71M with a range of €694.80M to €725.77M. The previous quarter’s sales results were €745.00M. DIM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 53.52% of the time in the same period. In the last calendar year DIM has Outperformed its overall industry.

DIM Stock Forecast FAQ

What is FR:DIM’s average 12-month price target, according to analysts?

Based on analyst ratings, Sartorius Stedim Biotech’s 12-month average price target is 229.38.

What is FR:DIM’s upside potential, based on the analysts’ average price target?

Sartorius Stedim Biotech has 36.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sartorius Stedim Biotech a Buy, Sell or Hold?

Sartorius Stedim Biotech has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Sartorius Stedim Biotech’s share price target?

The average share price target for Sartorius Stedim Biotech is 229.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €245.00 ,and the lowest forecast is €210.00. The average share price target represents 36.86% Increase from the current price of €167.6.

What do analysts say about Sartorius Stedim Biotech?

Sartorius Stedim Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Sartorius Stedim Biotech?

To buy shares of FR:DIM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sartorius Stedim Biotech (DIM) Stock Forecast & Price Target

DIM Analyst Ratings

DIM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sartorius Stedim Biotech

DIM Analyst Recommendation Trends

DIM Financial Forecast

DIM Earnings Forecast

DIM Sales Forecast

DIM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts